ALDA Pharmaceuticals Corp : ALDA recommends support for proposed share consolidation

NEWS RELEASE

APH:TSX-V, APCSF:OTCQB January 13, 2012

ALDA recommends support for proposed share consolidation

Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V) (the "Company" or "ALDA") has proposed a consolidation of its common shares ("the Consolidation") and the acquisition of one or more market-ready natural products ("the Acquisition").
ALDA's management and Directors are recommending that shareholders support the Consolidation at the Company's Annual General and Special Meeting ("the Meeting") to be held on January 27, 2012. Further details on the Meeting are contained in the Information Circular posted under the Company's profile at www.sedar.com.
Currently, the Company's shares are suspended. To meet the listing requirements of the Exchange and be reinstated, financing will be required. A share consolidation will facilitate such financing. Also, the Acquisition is dependent on the Consolidation.
Approval of the Consolidation will provide the Company with a better opportunity to continue in business and provide returns to shareholders.
If the Consolidation is not approved, the possibility of obtaining financing and completing the Acquisition would be reduced. It is also likely that the Company would be moved to the NEX and its ability to continue in business would be severely compromised.
The following summarizes information previously provided by the Company.

• The Consolidation involves the conversion of up to twenty (20) old common shares of the Company to one (1) new common share of the Company.

• The products under consideration for the Acquisition include a liquid multivitamin formulation for neonatal and natal care and an iron deficiency treatment containing a proprietary biological haemoglobin-protein complex. Both products have been provided with Natural Product Numbers and are market-ready. More information on these products is available in the news release issued by the Company on January 6, 2012.

At this time, further development of T36® therapeutic products is dependent on further financing. Shareholders requiring more information or assistance with voting are encouraged to contact Terrance
Owen, President & CEO, at 604-862-3439 or [e-mail].
Terrance Owen
President & CEO
ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp. Facsimile [604] 521.8322

www.aldacorp.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward- looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

ALDA Pharmaceuticals Corp. Facsimile [604] 521.8322

www.aldacorp.com